https://www.selleckchem.com/pr....oducts/dabrafenib-gs
ry-based interventions are urgently required to support the specific needs of patients deciding whether to participate in cancer trials. To evaluate a model for calculating the risk of AF and its relationship with the incidence of ischemic stroke and prevalence of cognitive decline. It was a multicenter, observational, retrospective, community-based study of a cohort of general population ≥6ct 35 years, between 01/01/2016 and 31/12/2018. Setting Primary Care. Participants 46,706 people ≥65 years with an active medical hist